Phaseline

Targets › CD45

CD45 (Receptor-type tyrosine-protein phosphatase C): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Jun 2027.

Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. (UniProt, P08575)

Open in Phaseline: the race on CD45, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fred Hutchinson Cancer Center211At-BC8-B10
Anti-CD45 monoclonal antibody conjugated to astatine-211 for pretargeted radioimmunotherap
CD45Phase 1Acute Lymphoblastic LeukemiaJun 2027
University of PennsylvaniaCD45BE-HSPC
CD45 base edited hematopoietic stem and progenitor cells
CD45Phase 1B-Cell Non-Hodgkin Lymphoma (NHL)Jul 2051

Conditions

Acute Lymphoblastic Leukemia (1) B-Cell Non-Hodgkin Lymphoma (NHL) (1)

Modalities

mixed (2)

Companies

Fred Hutchinson Cancer Center (1) University of Pennsylvania (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.